Cachet Pharmaceutical Co Ltd (002462) - Total Assets
Based on the latest financial reports, Cachet Pharmaceutical Co Ltd (002462) holds total assets worth CN¥11.93 Billion CNY (≈ $1.75 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Cachet Pharmaceutical Co Ltd for net asset value and shareholders' equity analysis.
Cachet Pharmaceutical Co Ltd - Total Assets Trend (2007–2025)
This chart illustrates how Cachet Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Cachet Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Cachet Pharmaceutical Co Ltd's total assets of CN¥11.93 Billion consist of 92.8% current assets and 7.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 20.1% |
| Accounts Receivable | CN¥6.13 Billion | 48.1% |
| Inventory | CN¥2.47 Billion | 19.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥24.96 Million | 0.2% |
| Goodwill | CN¥346.51 Million | 2.7% |
Asset Composition Trend (2007–2025)
This chart illustrates how Cachet Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cachet Pharmaceutical Co Ltd (002462) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cachet Pharmaceutical Co Ltd's current assets represent 92.8% of total assets in 2025, an increase from 48.1% in 2007.
- Cash Position: Cash and equivalents constituted 20.1% of total assets in 2025, up from 11.3% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 6.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 48.1% of total assets.
Cachet Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Cachet Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Raia Drogasil S.A
SA:RADL3
|
Brazil | R$25.27 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.83 Billion |
|
Ji Yao Holding Group Co Ltd
SHE:300108
|
China | CN¥1.43 Billion |
|
Empreendimentos Pague Menos S.A
SA:PGMN3
|
Brazil | R$9.81 Billion |
|
d1000 Varejo Farma Participações S.A
SA:DMVF3
|
Brazil | R$1.95 Billion |
|
High Tide Inc
V:HITI
|
Canada | CA$346.42 Million |
|
Yifeng Pharmacy
SHG:603939
|
China | CN¥26.07 Billion |
|
Laobaixing Pharmacy
SHG:603883
|
China | CN¥19.91 Billion |
Cachet Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.86 | 1.73 | 1.48 |
| Quick Ratio | 1.45 | 1.35 | 1.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥5.12 Billion | CN¥5.26 Billion | CN¥4.07 Billion |
Cachet Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Cachet Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.92 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -9.2% |
| Total Assets | CN¥12.75 Billion |
| Market Capitalization | $597.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cachet Pharmaceutical Co Ltd's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cachet Pharmaceutical Co Ltd's assets decreased by 9.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cachet Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual total assets of Cachet Pharmaceutical Co Ltd from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥12.75 Billion ≈ $1.87 Billion |
-9.19% |
| 2024-12-31 | CN¥14.04 Billion ≈ $2.05 Billion |
-18.01% |
| 2023-12-31 | CN¥17.12 Billion ≈ $2.51 Billion |
+3.41% |
| 2022-12-31 | CN¥16.56 Billion ≈ $2.42 Billion |
+10.84% |
| 2021-12-31 | CN¥14.94 Billion ≈ $2.19 Billion |
+5.69% |
| 2020-12-31 | CN¥14.13 Billion ≈ $2.07 Billion |
+8.41% |
| 2019-12-31 | CN¥13.04 Billion ≈ $1.91 Billion |
+20.16% |
| 2018-12-31 | CN¥10.85 Billion ≈ $1.59 Billion |
+17.88% |
| 2017-12-31 | CN¥9.20 Billion ≈ $1.35 Billion |
+24.73% |
| 2016-12-31 | CN¥7.38 Billion ≈ $1.08 Billion |
+25.36% |
| 2015-12-31 | CN¥5.89 Billion ≈ $861.44 Million |
+29.46% |
| 2014-12-31 | CN¥4.55 Billion ≈ $665.41 Million |
+63.08% |
| 2013-12-31 | CN¥2.79 Billion ≈ $408.02 Million |
+45.24% |
| 2012-12-31 | CN¥1.92 Billion ≈ $280.93 Million |
+21.60% |
| 2011-12-31 | CN¥1.58 Billion ≈ $231.03 Million |
+10.62% |
| 2010-12-31 | CN¥1.43 Billion ≈ $208.84 Million |
+55.59% |
| 2009-12-31 | CN¥917.28 Million ≈ $134.23 Million |
+24.94% |
| 2008-12-31 | CN¥734.16 Million ≈ $107.43 Million |
-14.49% |
| 2007-12-31 | CN¥858.54 Million ≈ $125.63 Million |
-- |
About Cachet Pharmaceutical Co Ltd
Cachet Pharmaceutical Co., Ltd. engages in the wholesale, retail, and logistics of pharmaceutical products in China. The company also offers medical drugs, medical devices, e-commerce products, and warehousing logistics services. It sells its products through online and offline channels. The company was founded in 1997 and is headquartered in Beijing, China.